Vanessa Research, Inc. (VRI) – a Connecticut-based biomedical company discovering, developing, and commercializing innovative products in areas of unmet medical needs – announced the appointment of John P. DeMezzo as Executive Vice President of Business Development & Strategy. DeMezzo will serve as a key member of the growing start-up’s executive leadership team, and as a visionary behind strategic decisions that will drive the success of VRI’s portfolio of brands.
DeMezzo comes to Vanessa Research with over 30 years of experience in multiple facets of the business field. His career began in sales, where he worked his way up from account and territory management roles to devising national and global sales programs for leading broadcast technology companies, Avid Technology and Discreet Logic. Proving adept at identifying emerging trends, market dynamics, and scalable monetization models; he went on to serve as Vice President of Business Development at the boutique private equity firm, Marblehead Capital Group, where he was instrumental in crafting strategies, business plans, and supportive budgets for portfolio companies.
Most recently, DeMezzo served as Senior Associate Vice President of Development and Alumni Affairs at Quinnipiac University. Being a graduate of the Quinnipiac University School of Business, he initially returned to his alma mater to help support the university’s strategic initiatives. As SAVP, he is credited with redeveloping critical foundational fundraising areas, resulting in increased alumni participation and record annual giving. Additionally, his leadership was critical to both gaining acceptance and securing the funding to construct the university’s highly-regarded Center for Religion.
Commenting on his new position at Vanessa Research, DeMezzo stated: “I am excited to join the company at such a pivotal point. My background in working with organizations at a start-up level will be put to good use. At VRI, I intend to collaborate with the executive team to construct strategies that will drive our brands and product sales forward – helping the company to address unmet market needs and ultimately, to give hope where none existed.”
About Vanessa Research
Vanessa Research, Inc. (VRI) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. VRI’s continually-expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease.
VRI is based in Hamden, Connecticut, with offices in Farmington, Connecticut; London, England; Budapest, Hungary; and Navarre, Spain.